Vaccine Info

Covaxin COVID-19 Vaccine

Authored by
Last reviewed
January 19, 2022

Covaxin COVID-19 Vaccine (BBV152) Description

Bharat Biotech's Covaxin (BBV152) is an inactivated COVID-19 vaccine that uses adjuvant Alhydroxiquim-II to boost immune response longer-lasting immunity. The Indian Council of Medical Research created the Covaxin (BBV152) vaccine. 

The COVAXIN (BBV152) vaccine contains six µg of whole-virion inactivated SARS-CoV-2 antigen (Strain: NIV-2020-770), and the other inactive ingredients such as aluminum hydroxide gel (250 µg), TLR 7/8 agonist (imidazoquinolinone) 15 µg, 2-phenoxyethanol 2.5 mg, and phosphate ® buffer saline up to 0.5 ml. The components of the Covaxin vaccine include BBV152A, BBV152B, and BBV152C. In addition, the virus strain is soaked in beta-propiolactone, an organic compound that deactivates them by binding to their genes, says the Company. The SARS-CoV-2 betacoronavirus strain was isolated from an asymptomatic COVID-19 patient at India's National Institute of Virology

Inactivated vaccines do not replicate and are unlikely to revert and cause pathological effects, says the U.S. CDC. The vaccine's adjuvant was developed with funding from the U.S. National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine. The TLR7/8 adjuvant formulation induced significant Th1 biased antibody responses and increased SARS-CoV-2 lymphocyte responses.

On March 8, 2021, The Lancet published a study that concluded by saying, 'In the phase 1 trial, BBV152 induced high neutralizing antibody responses that remained elevated in all participants at three months after the second vaccination. In the phase 2 trial, BBV152 showed better reactogenicity and safety outcomes and enhanced humoral and cell-mediated immune responses compared with the phase 1 trial. Therefore, the 6 μg with Algel-IMDG formulation has been selected for the phase 3 efficacy trial.'

On April 21, 2021, Bharat Biotech announced phase 3 interim analysis results of COVAXIN. The second interim analysis results in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease. The efficacy against severe COVID-19 disease was 100% (95%CI: 60-100), impacting reduction in hospitalizations. In addition, the efficacy against asymptomatic COVID-19 infection was 70%, suggesting decreased transmission in COVAXIN® recipients.

Then, on November 11, 2021, The Lancet published the results from a phase 3 study that reported 'BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. Vaccination was well tolerated with no safety concerns raised in this interim analysis.' And on November 23, 2021, The Lancet published another study that concluded the adjusted effectiveness of two doses administered at least 14 days before testing was 47% (95% CI 29–61). And non-peer-reviewed studies published on December 15, 2021, and January 8, 2022, found the inactivated virus vaccine BBV152 induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least six months after vaccination. 

The WHO confirmed it granted emergency use listing to COVAXIN® developed by Bharat Biotech on November 3, 2021, and issued Interim recommendations for the use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19. And the WHO is tracking SARS-CoV-2 virus variants of concern. Covaxin (BBV152) Accession Number: DB15847; UNII: 76JZE5DSN6 Covaxin clinical trials are listed.

Covaxin COVID-19 Vaccine (BBV152) Effectiveness Against Variants (Omicron)

Ocugen, Inc. and Bharat Biotech announced on January 12, 2022, results from a phase 1/2 clinical study conducted at Emory University in Georga demonstrating that sera from subjects who received a booster dose of candidate vaccine COVAXIN six months after getting a primary two-dose series of COVAXIN neutralized the SARS-CoV-2 Omicron and Delta variants. Earlier studies demonstrated the neutralizing potential of COVAXIN™ (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta, and Kappa.

As of January 19, 2022, the U.S. NIH's OpenData Portal reported in vitro Therapeutic Activity against the Omicron variant. But, given the breaking nature of these releases, Omicron data should be interpreted with caution. The U.S. CDC publishes updated virus variant information in this Tracker App. And the WHO publishes Tracking SARS-CoV-2 Variants on this webpage.

A recent study found Covaxin strongly protected New Delhi healthcare workers against reinfection with the virus in the first half of 2021, including a period during the height of the Delta variant surge. Among those who were fully vaccinated, the estimated effectiveness of the vaccine against reinfection was 86% (95% CI: 77% – 92%)

Covaxin COVID-19 Vaccine (BBV152) Booster Dose

A non-peer-reviewed study published on January 8, 2022, found participants receiving a booster dose six months after the second dose of COVAXIN™ saw a significant increase (>10-fold across Alpha, Beta, Delta, and Delta Plus variants) in neutralizing titers compared to baseline at six months.

January 19, 2022, local media in India report a limited clinical study that will evaluate the CorbeVax vaccine effectiveness as a booster (3rd) dose following two doses of Covaxin.

Covaxin COVID-19 Vaccine (BBV152) History

On September 23, 2020, Bharat Biotech announced a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp adenovirus, a single-dose intranasal vaccine for COVID-19. Bharat Biotech owns the vaccine's rights in all markets except the USA, Japan, and Europe.

On September 28, 2020, ViroVax LLC licensed its adjuvant, Alhydroxiquim-II technology, to Bharat Biotech to produce Covaxin. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's Bio-Safety Level 3 High-Containment facility in Genome Valley, Hyderabad, India.

On January 3, 2021, the Central Drugs Standard Control Organisation in India recommended emergency use permission. On May 10, 2021, local media reported the Haffkine Institute located in Mumbai, India, can produce 22.8 crore Covaxin vaccine doses annually, and the roll-out will take around eight to 10 months. On June 4, 2021, a non-peer-reviewed study found 'Covaxin vaccinated healthcare workers could produce a high immune response in up to 95% of recipients and prevent serious disease in those infected after immunization.' In addition, GAVI confirmed that India's "Covaxin" vaccine is highly effective against COVID-19 infections in phase 3 clinical trial on July 6, 2021.

Hyderabad-based Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians worldwide. Chiron Behring Vaccines became a subsidiary in 2019.

Covaxin COVID-19 Vaccine (BBV152) Indication

Individuals with HIV infection or other immunocompromising conditions or who take immunosuppressive medications or therapies might be at increased risk for severe COVID-19. However, data is NOT currently available to establish vaccine safety and efficacy in these groups. In addition, individuals with immunosuppression may not generate a complete immune response to COVID-19. There is no scientific information yet available on the appropriateness of COVAXIN along with other vaccines.

Covaxin COVID-19 Vaccine (BBV152) While Pregnant or Breastfeeding

If you are pregnant or breastfeeding, you should not get the vaccine as the effect of the vaccine has not been studied in pregnant women and nursing mothers says the Company.

Covaxin COVID-19 Vaccine (BBV152) For Children and Adolescents 

A Phase 2/3, open-label, multicenter study was conducted in India from May 2021 to July 2021, to evaluate COVAXIN - BBV152 in healthy volunteers 2-18 years of age. All participants received two doses of the whole virion inactivated SARS-CoV-2 virus vaccine 28 days apart. The neutralizing antibody responses against wild-type strain in the pediatric age group of 2-18 years were equivalent to those seen in adults, ages 18+ years, in Bharat Biotech's large Phase 3 efficacy and safety trial. More than 90% of the seroconversion rates were observed for antibody titers against S1, RBD, N proteins, and wild-type neutralizing antibodies.

The Times of India reported October 12, 2021, India's Subject Expert Committee committee recommended grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in emergencies subject to certain conditions. On December 25, 2021, Covaxin was approved for 12 and 18-year-olds by the Drugs Controller General of India.

On November 5, 2021, Ocugen, Inc. submitted a request to the U.S. FDA for a EUA for pediatric use.

Covaxin COVID-19 Vaccine (BBV152) Side Effects and Risks

Side effects that have been reported with COVAXIN (BBV152) include, but are not limited to, Injection site pain, Swelling, Redness, Itching, Headache, Fever, Malaise/body ache, Nausea, Vomiting Rashes. A severe allergic reaction may very rarely occur after getting a dose of COVAXIN. However, serious and unexpected side effects may occur.

On July 2, 2021, a non-peer-reviewed study found the 'BBV152 vaccine was well tolerated with no clinically or statistically significant differences in the distributions of solicited, unsolicited, or serious adverse events between vaccine and placebo groups.' Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% feeling serious adverse events.

A case report was published on September 12, 2021: Recurrent herpes zoster after COVID-19 vaccination in three patients with chronic urticaria being treated with cyclosporine.

Covaxin - Ocugen Agreement

Ocugen, Inc., a Pennsylvania-based biopharmaceutical company, and India-based Bharat Biotech announced on February 2, 2021, they entered into a definitive agreement to co-develop, supply, and commercialize COVAXIN in the United States. Under the agreement terms, Ocugen will have U.S. rights to the vaccine and be responsible for clinical development, regulatory approval, and commercialization for the USA. In addition, on June 3, 2021, the companies amendment to their Co-development to expand Ocugen's exclusive territory to commercialize COVAXIN to include Canada.

Ocugen, Inc. announced on June 10, 2021, that upon recommendation from the U.S. FDA, it would pursue submission of a biologics license application for the COVAXIN vaccine. On June 15, 2021, Ocugen announced that it had selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for Covaxin to prepare for potential commercial manufacturing for the U.S. and Canadian markets. The Company announced the completion of its regulatory submission to Health Canada for COVAXIN. The submission was conducted through the Company's new affiliate, Vaccigen, Ltd. 

On October 27, 2021, Ocugen Inc. confirmed it has submitted an Investigational New Drug (IND) application with the U.S. FDA. And on November 5, 2021, Ocugen submitted an application for pediatric use in the U.S. On November 26, 2021, Ocugen announced that the U.S. FDA issued a clinical hold on the Company's IND.

Ocugen reported on November 9, 2021, its cash, cash equivalents, and restricted cash totaled $107.5 million as of September 30, 2021. Ocugen reported a $0.05 net loss per share for the three months ended September 30, 2021, compared to a $0.07 net loss per share for the three months ended September 30, 2020, which includes the in-process research and development expense of $7.0 million related to the reduction of the carrying value of an asset that was previously recorded as held for sale.

Covaxin COVID-19 Vaccine (BBV152) Availability

Covaxin was granted Emergency Use Listing by the World Health Organization on November 3, 2021. Furthermore, UNICEF, Pan-American Health Organization, and the GAVI COVAX facility will be able to procure COVAXIN for distribution to countries worldwide. Over 17 countries authorizing the Covaxin vaccine are listed on this webpage.

Covaxin COVID-19 Vaccine (BBV152) Price

As of April 2021, Covaxin cost in India is about 295 rupees (US$ 3.97).

Covaxin COVID-9 Nasal Vaccine (BBV154) News

The Company requested authorization on December 20, 2021, to use the nasal vaccine as a booster dose.

Covaxin COVID-19 Vaccine (BBV152) News

January 13, 2022 - Local media reported Bharat Biotech announced that Coavaxin is now a universal vaccine for adults and children. Elaborating further, Bharat Biotech stated, "Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed." 

January 12, 2022 - Ocugen, Inc. and Bharat Biotech issued a press release stating a booster (3rd) dose of COVAXIN generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay; and 100% of test serum samples in the phase 1/2 study showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant.

January 3, 2022 - The Times of India reported a study led by AIG Hospitals determined mixing Covishield and Covaxin vaccines "conclusively showed that mixing of vaccines is absolutely safe", and the spike-protein neutralizing antibodies in the mixed vaccine groups were found to be significantly higher than the same-vaccine groups.

December 30, 2021 - Ocugen, Inc. announced today that its partner, Bharat Biotech, posted results on (Dec. 29) from a Phase 2/3 trial conducted in India of COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile.

December 25, 2021 - Local media reported the Covaxin was approved for emergency use on adolescents 12 and 18 tears of age by the Drugs Controller General of India.

December 20, 2021 - The Company announced India's Central Drugs Standard Control Organisation has approved the extension of Covaxin's shelf life up to 12 months from the date of manufacture.

December 17, 2021 - Bharat Biotech and its local partner Dunc Minh have donated 200,000 doses of Covaxin to the Republic of Vietnam.

December 15, 2021 - Ocugen, Inc. announced that data analyzing immune response following two doses of COVAXIN™ (BBV152), compared the immune memory response of 71 vaccinated and 73 naturally infected subjects with SARS-CoV-2, including variants of concern, for up to six months. The study found that COVAXIN generated a robust immune memory against spike and nucleoprotein that was comparable to that following natural COVID-19 infection for the levels of antibodies, memory B cells, and memory CD4+ T cells. In the analysis, COVAXIN generated T-cells against both spike and nucleocapsid proteins in nearly 85% of subjects that persisted for at least 6 months.

December 14, 2021 - Local media reported the Rajya Sabha was informed about 50-60 million doses of the Covaxin vaccine are being produced.

December 9, 2021 - Media sources reported the WHO's Strategic Advisory Group of Experts on Immunisation said people who are immune-compromised (such as those on dialysis or immuno-suppressants) or have received an inactivated Covid-19 vaccine, such as Covaxin, should receive boosters to protect them against waning antibodies.

December 3, 2021 - India's Central Drugs Standard Organisation approved the shelf life of COVID-19 vaccines Covaxin to 12 months.

November 29, 2021 - "Bharat Biotech has commenced exports of Covaxin. Long pending orders have been executed during November 2021, to be further expanded during the following months. With the number of countries that have granted emergency use approvals for Covaxin increasing, exports to additional countries will also commence from December," Bharat Biotech said in an announcement posted on Twitter.

November 23, 2021 - This study published by The Lancet is, to our knowledge, the first real-world observational study assessing vaccine effectiveness of BBV152. We found vaccine effectiveness of 50% (95% CI 33–62) for complete vaccination at least 14 days before testing, against symptomatic laboratory-confirmed COVID-19. 

November 22, 2021 - The U.K. added the Covaxin vaccine to its travel approval list, requiring at least 14 days of immunization before arriving in England.

November 19, 2021 - The Government of Canada announced adjustments to recognize the Covaxin vaccine within acceptable border measures. Travelers should check if they are eligible to enter Canada and meet all entry requirements before heading to the border. 

November 18, 2021 - According to a Twitter post by ANI, 110 countries agreed to mutual acceptance of vaccination certificates with Covaxin.

November 16, 2021 - New Zealand health leader Tweeted the Covaxin vaccine would be acceptable for border entry requirements.

November 11, 2021 - The Lancet published a study: Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomized, double-blind, controlled, phase 3 trial. Findings: 24 (0·3%) cases occurred among 8471 vaccine recipients and 106 (1·2%) among 8502 placebo recipients, giving an overall estimated vaccine efficacy of 77·8% (95% CI 65·2–86·4).

November 8, 2021 - The U.K. government confirmed Covaxin was added to the country's approved list of vaccines for inbound travelers.

November 5, 2021 - Ocugen, Inc. announced that it has submitted a request to the U.S. FDA for EUA of Ocugen's COVID-19 vaccine candidate BBV152, known as COVAXIN outside of the U.S., for pediatric use.

November 3, 2021 - The World Health Organization issued an emergency use listing for COVAXIN developed by Bharat Biotech. "This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic," said Dr. Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products.

November 1, 2021 - Australia's TGA determined that Covaxin (manufactured by Bharat Biotech, India) vaccine would be 'recognized' for the purpose of establishing a traveler's vaccination status.

October 28, 2021 - ANI reported India intends to procure six crore doses of the Covaxin vaccine in November 2021.

October 27, 2021 - "We are very excited to take this next step in the development of COVAXIN™, which we hope will bring us closer to introducing a different type of COVID-19 vaccine to the American public," said Dr. Shankar Musunuri, Chairman of the Board, CEO, and Co-Founder of Ocugen, in a press statement. "We are hopeful that the study conducted under a U.S. FDA IND if allowed to proceed, will help demonstrate that the data from India will be applicable to the U.S. population."

October 25, 2021 - Tribune News Service reported the WHO's Soumya Swaminathan confirmed "The (WHO) technical advisory group will meet on October 26th to consider emergency use listing for Covaxin."

October 15, 2021 - A new study: Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin, studied eighteen participants who received heterologous vaccination regimen of AstraZeneca's ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participants did not report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response. Covaxin vaccination-induced enhanced cytokine and chemokine responses as early as month 1, following prime-boost vaccination, indicating robust activation of innate and adaptive immune responses in vaccine recipients.

October 12, 2021 - India's Subject Expert Committee expert panel granted emergency use approval to Bharat Biotech's Covaxin vaccine for children between the ages of two and 18.

October 11, 2021 - ANI News reported Covaxin vaccine clinical trials with children show similar results as on adults, stated Dr. Sanjay K Rai, Professor at the Centre for Community Medicine.

October 7, 2021 - Media reported the Union government of India had approved the export of 10 lakh Covaxin vaccine doses to Iran.

October 2, 2021 - Local media reported Bharat Biotech submitted clinical trial data to the DCGI on Covaxin vaccine use for children in the 2-18 years age group, seeking authorization.

September 28, 2021 - Local media reported Bharat Biotech had submitted all the necessary documents required for WHO approval on July 9, 2021.

September 22, 2021 - The World Health Organisation's Strategic Advisory Group of Experts on Immunization will be meeting on October 5, 2021, to consider granting the Covaxin vaccine authorization. The meeting agenda indicates the Company will present evidence and draft recommendations on the use of the Bharat Biotech vaccine in priority populations.

September 22, 2021 - The Hindustan Times reported Bharat Biotech confirmed the Phase 2/3 trials of Covaxin for children under the age of 18 are over. The Company also said that it expects to submit the dataIndia'sia's Drug Controller General of India by next week.

September 21, 2021 - Bharat Biotech's Krishna Ella informed media the Company is planning to ramp up production of its Covaxin vaccine from 3.5 crore doses this month to 5.5 crore doses in October 2021.

August 29, 2021 - Local media in India reported "We want to ensure that Bharat Biotech can ably meet the demand for Covaxin such that individuals across the country, and the globe, have access to the vaccine," Company's chairman and managing director Krishna Ella said in a recent statement.

August 26, 2021 - LocalCircles conducted a nationwide survey to understand better what (40,000) citizens in India experienced after 1st and 2nd dose of COVAXIN. On an aggregate basis, 78% of citizens surveyed experienced no or mild side effects—sore arm or fatigue after taking the 2nd dose of Covaxin.

August 24, 2021 - Manila media reported the Philippines Department of Science and Technology-VEP member Dr. Rontgene Solante said that Covaxin is at least 80% effective against the severe form of COVID-19 illness.

August 15, 2021 - Dr. Krishna Ella, chairman and managing director of Bharat Biotech, was reported to have said The Freedom Summit the Company is working on a combination of Covaxin followed by a nasal vaccine so that Covaxin primes the system of innate immunity and then the boost by the nasal which produces three immune responses, the IGG, the IGA and then mucosal immunity, all three of which are powerful and can protect a person from getting infected.

August 7, 2021 - A non-peer-reviewed study in India suggests that immunization with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine (Covaxin) was not only safe but also elicited better immunogenicity. The immunogenicity profile against Alpha, Beta, and Delta variants in the heterologous group was superior; IgG antibody and neutralizing antibody response of the participants was also significantly higher than that in the homologous groups. 

August 5, 2021 - Bharat Biotech announced via Twitter European regulatory in Hungary has certified Covaxin. This marks the 1st EUDRAGDMP compliance certificate issued for Covaxin.

August 2, 2021 - Covaxin was reported effective against SARS-CoV-2 coronavirus variants, according to a study conducted by the Indian Council of Medical Research. In conclusion, this non-peer-reviewed study stated 'reduction in the NAb titer was observed in the sera of fully immunized Covid naïve, recovered cases with BBV152 vaccination, and breakthrough cases. However, with the observed high titers, the sera of individuals belonging to all the aforementioned groups would still neutralize the Delta, Delta AY.1, and B.1.617.3 variants effectively.

July 31, 2021 - Local media reported India's Subject Expert Committee approved Bharat Biotech's plan to experiment with a mixed-dosing of the intramuscularly administered Covaxin and a nasal inoculation based on a different vector.

July 23, 2021 - Media reported Bharat Biotech committed to supplying over 500 million doses of its Covaxin vaccine to the Centre under the countrywide immunization program. Speaking at a virtual conference, Suchitra Ella, joint Managing Director of Bharat Biotech, said the Company's facilities in Hyderabad, Bengaluru, Pune, and Ankaleshwar are currently producing Covaxin.

July 23, 2021 - Bharat Biotech confirmed it terminated a Memorandum of Understanding with Precisa Medicamentos and Envixia Pharmaceuticals LL.C to produce its Covaxin for the Brazilian market. Media reported, "Notwithstanding such termination, Bharat Biotech will continue to work diligently with ANVISA, the Brazilian drug regulatory body, to complete the regulatory approval process for Covaxin.

July 19, 2021 - Bharat Biotech's Covaxin for children aged 2-6 years is likely to be administered to those participating in the trials next week, according to local media. The second dose of Covaxin has already been given to children between ages 6-12 years, said sources, at the All India Institute of Medical Sciences.

July 7, 2021 - The Hindustan Times reported, "The application of the booster (3rd) dose will depend on the knowledge of the efficacy of the vaccine. It is well known that natural antibodies after infection remain for 7-12 months. But the jury is still out to decide how long vaccine-generated antibodies remain effective, stated Dr. Balram Bhargava, director-general, the Indian Council of Medical Research.

July 6, 2021 - Gavi published an article India's Covaxin vaccine shows high efficacy against COVID-19 infections in a phase 3 trial. Covaxin, also known as BBV152, was authorized for emergency useIndia'sia's Central Drugs and Standards Committee (CDSCO) on 3 January 2021, even though phase 2 clinical trials were unpublished and larger phase 3 trials still ongoing.

July 3, 2021 - Bharat Biotech announced safety and efficacy analysis data today from Phase III clinical trials of COVAXIN. Efficacy analysis demonstrates COVAXIN® to be 93.4% effective against severe symptomatic COVID-19. And Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant. Prof. Priya Abraham, Director National Institute of Virology ICMR, said, "The overall efficacy of 77.8 % following the phase III clinical trial of COVAXIN® is wonderful news."

July 2, 2021 - A non-peer-reviewed study funded by the vaccine owner found BBV152 was immunogenic and highly efficacious against symptomatic and asymptomatic COVID 19 variant associated disease, particularly against severe disease in adults. Vaccination was well tolerated, with an overall incidence of adverse events observed over a median of 146 days lower than other COVID-19 vaccines.

June 29, 2021 - An adjuvant developed with funding from the National Institutes of Health has contributed to the success of the highly efficacious COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, part of NIH, said in a press statement "I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India."

June 25, 2021 - The Philippines Food and Drug Administration granted full emergency use authorization to the Covaxin COVID-19 vaccine developed by India-based Bharat Biotech.

June 9, 2021 - Local media reported 'Bharat Biotech will conduct phase 4 clinical trials for Covaxin to check its real-world effectiveness. And, the Company will apply for full licensure after a final analysis of Phase 3 studies.

June 7, 2021 - A non-peer-reviewed study found 'the whole-virion inactivated SARS-CoV-2 vaccine (BBV152) demonstrates protective response against VOC B.1351 and B.1.61'.2.'

June 5, 2020 - Brazil's National Health Surveillance Agency cleared BhaBiotech'sch's Covaxin vaccine for importation into Brazil.

June 3, 2021 - Local media reported 'the majority of the breakthrough infections following vaccination with Covishield and Covaxin were caused by SARS CoV2 lineage, which found to be the predominant lineage with 23 samples (63.9%) out of which 12 were in fully vaccinated and 11 in partially vaccinated groups. In addition, four samples with 11.1% and 1 sample with 2.8% were assigned the lineages B.1.617.1 and B.1.1.7 respectively, according to the non-peer-reviewed study.

June 2, 2021 - Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per year of the Covaxin vaccine with Bharat Biotech.

May 27, 2021 - The Tribune reported, 'The Ministry of Health said trials for a booster dose of Covaxin were underway. Once the need and the duration of booster shots for available Covid vaccines worldwide are known, related protocols on booster doses will also be made available.'

May 24, 2021 - Bharat Biotech launched trials for the third booster dose of Covaxin at the All India Institute of Medical Sciences in Delhi and Patna, reported All India Radio.

May 15, 2021 -  ANI reported the Centre plans is to increase production from 1.5 crore vaccine doses to 10 crore doses monthly.

May 12, 2021 - Local media reporIndia'sia's Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organization authorized Bharat Biotech to conduct phase II/III clinical trials to evaluate the safety, reactogenicity, and immunogenicity of Covaxin vaccination in people aged 2 to 18 years.

May 11, 2021 - The Government of Maharashtra announced the suspension of the COVID-19 vaccination drive for the 18-44 age group due to a shortage of jabs. State Health Minister Rajesh Tope told the media that the government had prioritized the second dose of the 45+ age group people with the remaining stock of vaccines. The minister said the move, however, is temporary.

May 7, 2021 - The Indian Council of Medical Research (ICMR) confirmed it is willing to share the know-how to produce the Covaxin vaccine with any company. Bharat Biotech has the sole license to manufacture Covaxin, which it developed in collaboration with scientists fICMR'sMR's Pune-based National Institute of Virology, reported local media.

May 3, 202India'sia's Ministry of Health and Family Welfare confirmed 100% advance of Rs. 787.50 cr (after TDS Rs. 772.50 cr) was released on 28.04.2021 to Bharat Biotech India Ltd (BBIL) for 05 crore Covaxin doses during May, June, and July and was received by them on 28.04.2021. To date, against the last order of 02 crore doses for supplies of the Covaxin vaccine, 0.8813 crore doses have been delivered till 03.05.2021. And, Under the Liberalised Pricing & Accelerated National COVID-19 Vaccination Strategy, the Govt of India would continue to procure its share of 50% of the monthly Central Drugs Laboratory cleared vaccines & would continue to make it available to the State Govts totally free of cost as was being done earlier.

May 3, 2021 - Scientists at the Indian Council of Medical Research-National Institute of Virology have found that Covaxin is effective against the Brazil variant, B.1.128.2. This finding comes after their study that suggested that Covaxin was effective against the U.K. variant and the Indian (double mutant) variant B.1.617.

April 21, 2021 - BhaBiotech'sch's Phase 3 clinical trial's second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. However, due to the recent surge in cases in India, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease. The efficacy against asymptomatic COVID-19 infection was 70%, based on a subgroup of approximately 8,000 participants who visited the clinical trial site each month for an RT-PCR test.

April 20, 2021 - The BMJ published: What do we know about India's Covaxin vaccine?

April 16, 2021 - Local media reported the New Delhi-based Indian government would double the production of the indigenous Covaxin vaccine by May 2021 and increase it nearly seven-fold by August 2021.

April 13, 2021 - A non-peer-reviewed study assessed the humoral immune response after the first dose of two vaccines ChAdOx1-nCOV (Covishield) and the BBV-152 (Covaxin), in Indian healthcare workers. These researchers concluded, 'While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient than Covaxin after the first dose. Ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose.'

April 9, 2021 - India has administered over 9.4 crore COVID-19 doses, according to the statement released by the ministry of health and family welfare.

April 6, 2021 - Mexico'sco's health regulator Cofepris has authorized the emergency useIndia'sia's COVID-19 vaccine COVAXIN.

March 19, 2021 - Nepal'sal's Department of Drug Administration issued emergency authorization for the Covaxin COVID-19 vaccine.

March 8, 2021 - The Lancet reported: The BBV152 vaccine, adjuvanted with alum and a TLR 7/8 agonist, is designed to enhance humoral and Th1-skewed cellular immune responses after immunization by optimizing the inactivated vaccine formulation. Overall, Algel-IMDG-adjuvanted BBV152 was safe, immunogenic, and able to induce Th1-biased T-cell responses and could be a potentially superior vaccine over the alum-adjuvanted inactivated COVID-19 vaccines. However, this is the only study of an inactivated COVID-19 vaccine candidate to report a thorough evaluation of cell-mediated responses. The 6 μg with Algel-IMDG formulation has been selected for the phase 3 efficacy trial. BBV152 (developed using a well-established manufacturing platform) was safe, immunogenic (persisting for 3 months), and stored at 2–8°C, compatible with most immunization cold chain requirements countries. Follow-up studies to assess the efficacy and immune responses in older adults and people with comorbidities are underway.

March 3, 2021 - Bharat Biotech announced the first interim analysis of its BBV152 (COVAXIN®). The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, partnering with the Indian Council of Medical Research. The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (COVAXIN®) group, resulting in a point estimate of vaccine efficacy of 80.6%. An interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via prepublication servers and submitted to a peer-reviewed journal for publication.

March 2, 2021 - The journal Nature published a study: Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Altogether, this study demonstrates that a two-dose vaccination regimen using a 3-µg dose of the vaccine candidate with adjuvant B induces a significant immune response and provides effective protection in animals challenged with SARS-CoV-2.

February 26, 2021 - Brazil'sil's health ministry announced it signed a contract to purchase 20 million doses of the Covaxin vaccine for delivery between March and May 2021.

February 19, 2021 - The Indian Council of Medical Research (ICMR) announced interim results of the ongoing Covaxin vaccine clinical trials indicated that the indigenous Covid-19 vaccine would be effective against SARS-CoV-2 coronavirus strains reported from the United Kingdom, South Africa, and Brazil. The Hindustan Times reported that the third clinical trial of Covaxin had been completed as all the 25,800 volunteers involved had been administered both doses.

February 18, 2021 - Reuters reported Bharat Biotech announced it is in the process of filing regulatory documents for approval of its COVID-19 vaccine, COVAXIN, in more than 40 countries.

February 2, 2021 - Ocugen, Inc. and Bharat Biotech announced they have entered into a definitive agreement to codevelop, supply, and commercialize BhaBiotech'sch's COVAXIN™, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.

January 23, 2021 - The Lancet published an artic'COVAXIN'sIN's approval in India came before the Company had finished recruiting for the drug's phase 3 trial. Given that there is no efficacy data for COVAXIN yet, some health work "rs "may not have confidence in COVAXIN, and that is understandable said Vineeta Bal, immunologist and visiting faculty from the Indian Institute of Science Education and Research, Pune. "The government needs to put out all data, including for efficacy, for the sake of transparency, and for building the confidence of the people," she said. "The lack of data for COVAXIN leaves those who have been given it in an uncertain position regarding their status. The vaccine may work out to be safe and efficacious, but that would be owed more to good luck than to good government policy", said Jammi Nagaraj Rao, a public health physician and epidemiologist.'

January 21, 2021 - The Lancet published a 'report on the interim findings from the phase 1 clinical trial of BBV152; a whole-virion inactivated SARS-CoV-2 vaccine.

January 12, 2021 - Bharat Biotech announced that it had signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

January 8, 2021 - Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. In addition, post-SARS-CoV-2 infection vaccinated hamsters did not show any histopathological changes in the lungs.

January 3, 2021 - India'sia's Drugs Controller General of India issued a Restricted Emergency approval for the emergency use of a coronavirus vaccine produced by local firm Bharat Biotech.

December 22, 2020 - Pennsylvania-based Ocugen, Inc. and Bharat Biotech announced that the companies had signed a binding letter to co-develop BhaBiotech'sch's COVID-19 vaccine candidate, COVAXIN, the United States market.

November 16, 2020 - Bharat Biotech has announced the commencement of Phase III trials of COVAXIN™. The Phase III trials will involve 26,000 volunteers across India, conducted in partnership with ICMR, the largest clinical trial conducted for a COVID-19 vaccine in India.

July 15, 2020 - Bharat Biotech announced the Phase-I clinical trialsIndia'sia's first indigenous COVID-19 vaccine, Covaxin, began across the country, enrolling 385 people in 12 hospitals.

June 29, 2020 - India's Covaxin has received permission to initiate Phase I & II Human clinical trials after the Company submitted results from preclinical studies, demonstrating safety and immune response.

May 8, 2020 - The Council of Scientific and Industrial Research, under its flagship program NMITLI, has sanctioned a project to develop human monoclonal antibodies as therapy for COVID-19 infections. The project is being led by Bharat Biotech, a leading manufacturer of vaccines and biotherapeutics and a product supplier to over 65 globally.

Covaxin COVID-19 Vaccine Clinical Trial

Covaxin continues to be tested in various clinical trials.

Clinical Trials: NCT05049187 - Observational study to determine the characterization and durability of COVID-19 Vaccine induced immunity responses in Healthcare/Frontline Workers

Clinical Trial: NCT04918797 - Phase 2/3 COVAXIN in a Pediatric Cohort (COVAXIN-Peds) study was last updated on July 2, 2021.

Clinical Trial: NCT04641481 - An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers.

Clinical Trial: NCT04471519 - Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers (BBV152). A total sample size of 755 healthy volunteers, with 375 and 380 volunteers in phase 1 and 2 studies, respectively.